Adial Pharmaceuticals adjourns votes on Nasdaq-dependent proposals, reconvenes meeting Oct. 26

Adial Pharmaceuticals (ADIL) reported Q2 2026 results ended June 30, 2026, including a Q2 net loss of $52.0M ($11.25/share) versus $2.0M in Q2 2025. Cash was $28.7M. The company completed the first $32M tranche of a $64M private placement and acquired Azora Therapeutics, adding AT177 for ulcerative colitis. ADIL stock fell to $3.98.

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adiel Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update Completed acquisition of Azora Therapeutics, adding AT177, a fully synthetic, oral, colon-targeted aryl hydrocarbon receptor (“Ahr”) agonist in development for ulcerative

Adial Pharmaceuticals said it will acquire Azora Therapeutics and obtain its lead asset AT177 for ulcerative colitis. The deal is paired with a $64 million private placement, including $32 million upfront, issuing pre-funded warrants for 11,780,948 shares at $2.7489. A further $32 million milestone is tied to Phase 1 start. Proceeds will fund AT177 development; proof-of-concept studies are planned for 2027.

ADIAL PHARMACEUTICALS, INC. (ADIL) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029444801ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED JUNE 11, BY AND AMONG ADIAL PHARMACEUTICALS, INC., ADIAL FIRST MERGER SUB, INC., ADIAL SECOND MERGER SUB, LLC AND AZORA THERAPEUTICS, INC Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among: Adi

bp agreed to pay Louisiana $350M to settle remaining Deepwater Horizon claims, accelerating payments under the 2015 settlement. The payment resolves coastal zone litigation and provides Louisiana with earlier access to funds. bp CEO Meg O’Neill noted the agreement supports the state's investment and job creation. The 2015 settlement totaled up to $18.7B, with $4.9B allocated to Gulf Coast states.

SK Hynix canceled plans for a $10 billion U.S. IPO of its Solidigm unit due to regulatory opposition and shareholder concerns, citing market conditions. The decision follows scrutiny over potential share dilution and ownership structure complexities. SK Hynix shares rose after the announcement, despite broader market declines. Solidigm, a major flash memory producer, had planned to list as soon as next year, aiming for a valuation of up to $100 billion.